Repairon Immuno GmbH is a startup with the mission to enhance existing and emerging CART therapies. To achieve this goal, we take advantage of worldwide licensed induced Pluripotent Stem Cell (iPSC) line, which is being validated in an European clinical trial. This cell line in combination with our proprietary, scalable, GMP-compliant differentiation platform as well as proprietary gene editing designs will enable us to generate never-done-before types of cell drug products to tune T cells and transform CART cell therapies, such as in vivo CART.

Repairon Immuno

Org chart

Teams

Offices